Loading...
Loading...
ITOS| Name | Value |
|---|---|
| Revenues | 35.0M |
| Cost of Revenue | 0.3M |
| Gross Profit | 34.7M |
| Operating Expense | 48.9M |
| Operating I/L | -14.2M |
| Other Income/Expense | 8.4M |
| Interest Income | 7.8M |
| Pretax | -5.8M |
| Income Tax Expense | 1.4M |
| Net Income/Loss | -7.1M |
Iteos Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in immuno-oncology therapeutics. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists in Phase 2 clinical trials, and EOS-448, an antagonist of TIGIT in Phase 1/2 clinical trial. These products are designed to engage the Fc gamma receptor to activate dendritic cells and macrophages, promoting antibody-dependent cellular cytotoxicity. Through the development and commercialization of these immuno-oncology therapeutics, Iteos Therapeutics, Inc. generates revenue from the sale of its innovative drugs to patients and healthcare providers.
